HLB Therapeutics Co (XKRX:115450) 5-Year EBITDA Growth Rate : 0.00% (As of Sep. 2024)

View and export this data going back to 2010. Start your Free Trial

What is HLB Therapeutics Co 5-Year EBITDA Growth Rate?

HLB Therapeutics Co's EBITDA per Share for the three months ended in Sep. 2024 was ₩-1.19.

During the past 12 months, HLB Therapeutics Co's average EBITDA Per Share Growth Rate was -638.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of HLB Therapeutics Co was 88.50% per year. The lowest was -184.00% per year. And the median was -0.15% per year.

Competitive Comparison of HLB Therapeutics Co's 5-Year EBITDA Growth Rate

For the Biotechnology subindustry, HLB Therapeutics Co's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HLB Therapeutics Co's 5-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HLB Therapeutics Co's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where HLB Therapeutics Co's 5-Year EBITDA Growth Rate falls into.

HLB Therapeutics Co 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

HLB Therapeutics Co (XKRX:115450) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

HLB Therapeutics Co 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of HLB Therapeutics Co's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

HLB Therapeutics Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HLB Therapeutics Co Ltd (XKRX:115450) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

22F, Parkview Tower, 6, Jeongja-Dong, Bundang-Gu, Seongnam-si, 463-863, KOR, 463-811

Website

https://www.hlbtherapeutics.co.kr

HLB Therapeutics Co Ltd is a bio company that pursues first-in-class and innovates new drug development. With the development and validation of new drugs for various hard-to-treat disorders, HLB Therapeutics is becoming a global biopharmaceutical company focused on alleviating patient suffering.

HLB Therapeutics Co Headlines

No Headlines